<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Therapeutic plasma exchange (plasmapheresis) with hemodialysis equipment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Therapeutic plasma exchange (plasmapheresis) with hemodialysis equipment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Therapeutic plasma exchange (plasmapheresis) with hemodialysis equipment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andre A Kaplan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rasheed A Balogun, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Traditionally, automated therapeutic plasma exchange (TPE; plasmapheresis) was performed with centrifugation devices used for donor apheresis and cell collections in blood banking. (See  <a class="medical medical_review" href="/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"</a>.)</p><p>Such devices permit selective cell removal (cytapheresis) but have been associated with posttreatment thrombocytopenia [<a href="#rid1">1,2</a>] and require a dedicated centrifuge device. An increasingly popular and often more efficient alternative is to perform therapeutic plasma exchange by membrane plasma separation (MPS) [<a href="#rid3">3-7</a>].</p><p>MPS utilizes a highly permeable membrane and a standard dialysis machine used in its ultrafiltration dialysis-bypass mode (similar to the technique in hemoperfusion). TPE is also possible using specialized dual-purpose NxStage and Prismaflex continuous kidney replacement therapy (CKRT) machines. The NxStage machine employs a cartridge that uses the Plasmaflo OP-05W as the filtration membrane. Prismaflex uses different sized membranes, the HF1000/HF1400 sets (for patient weight greater than 20 to 30 kg).</p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'Technical considerations'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14021.html" rel="external">"Short daily home hemodialysis: The low dialysate volume approach"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1845.html" rel="external">"Continuous kidney replacement therapy in acute kidney injury", section on 'Equipment'</a>.)</p><p></p><p>For many years, the most commonly used membrane in the United States was the Plasmaflo AP-05H. This filter has been replaced with a slightly more porous filter, the OP-05W [<a href="#rid8">8</a>]. This filter can be used with most dialysis machines, but the Cobe 3 and Hospal machines are incompatible with the filter's tubing.</p><p>The published American experience with MPS has historically been limited even though thousands of treatments were performed in the United States each year [<a href="#rid9">9-12</a>]. In some countries, such as Germany and Japan, 90 percent of plasmapheresis treatments are performed by MPS [<a href="#rid6">6,13</a>]. A series of 998 treatments performed with the NxStage system has been reported [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H2"><span class="h1">TECHNICAL CONSIDERATIONS</span><span class="headingEndMark"> — </span>When using the Plasmaflo filter with a standard dialysis machine, transmembrane pressure (TMP) should be modest (recommended TMP &lt;75 mmHg, although the maximum TMP for the OP-05W is listed as 100 mmHg), and blood flow is often 50 to 150 mL/min in order to minimize the tendency for hemolysis and filter clotting [<a href="#rid9">9,14</a>]. Utilizing an anticoagulation-free protocol, one report suggests that those treatments with an average TMP of 54.5 mmHg were more likely to clot than those with an average TMP of 43.7 mmHg [<a href="#rid12">12</a>]. Limiting TMP can be most easily achieved by limiting blood flow and by regulating filtrate output via use of a double roller pump on the filtrate output of the filter. This double pump also regulates the infusion of replacement fluid (such as albumin or fresh frozen plasma), matching its rate of return to the volume of plasma removed, thereby eliminating the risk of hypotension or fluid overload. Unfortunately, these double-roller pumps are difficult to find.</p><p>Manufacturers generally recommend a filtration fraction of less than 20 percent. In a report cited above [<a href="#rid12">12</a>], the average filtration fraction was 25 percent with a mean blood flow of 151 mL/min, a mean plasma removal rate (exchange rate) of 31 mL/min, and a mean therapy time of 116 min for a 3635 mL exchange. A more modest experience of 46 treatments with the Prismaflex system has been reported from Korea [<a href="#rid15">15</a>]. These treatments were performed with filtration fractions of 25 to 30 percent, mean treatment time of 130 minutes, mean blood flow of 140 mL/min, and net output of 3206 mL [<a href="#rid15">15</a>].</p><p>It is important to appreciate that rapid removal and infusion of protein-containing solutions produce volume changes that are essentially limited to the intravascular compartment. Thus, even small mismatches in net plasma removal rate will have a far greater effect on systemic blood pressure than would be produced by an equivalent water shift during standard hemodialysis [<a href="#rid16">16</a>].</p><p>The protein-permeable membranes, such as the Plasmaflo, are very susceptible to concentration polarization, a phenomenon whereby protein layering on the inner surface of the membrane rapidly limits the maximum achievable filtration rate [<a href="#rid4">4</a>]. As a result, inappropriately high TMPs will not yield higher filtration rates but will increase the tendency for the filter to clog  (<a class="graphic graphic_figure graphicRef52183" href="/d/graphic/52183.html" rel="external">figure 1</a>). Dialysis nursing issues have been the subject of several reviews [<a href="#rid14">14,17,18</a>].</p><p class="headingAnchor" id="H6472987"><span class="h2">Biocompatibility</span><span class="headingEndMark"> — </span>Testing of the OP-05W reveals a potential for increased bradykinin levels, and it would be wise to hold angiotensin-converting enzyme (ACE) inhibitors in any patient who is to be treated with this membrane [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Anticoagulation</span><span class="headingEndMark"> — </span>Most therapeutic plasma exchange (TPE) treatments performed with standard centrifugal devices use citrate anticoagulation. Although this technique can be modified for use with a membrane plasma separation (MPS) system [<a href="#rid12">12,19</a>], most MPS treatments are performed with heparin. A bolus of low-dose heparin (eg, 2000 units) can be given at the start of the treatment, unless anticoagulation is contraindicated. The heparin dose should be increased when the hematocrit is reduced. In this setting, there is a relative increase in plasma volume removal (since more of the blood is composed of plasma), leading to enhanced removal of heparin [<a href="#rid20">20</a>].</p><p>Initial recommendations had been to start with a heparin dose of 5000 units [<a href="#rid9">9</a>] or 40 to 60 units/kg [<a href="#rid14">14</a>] followed by a maintenance dose of approximately 1000 units per hour. However, a report from Columbia using no anticoagulation documented only one case of filter clotting occurring out of 500 MPS treatments (using Bellco or Edwards-Nikkiso membranes not available in the United States) [<a href="#rid21">21</a>]. In another report of nearly 1000 treatments using the NxStage machine with an anticoagulant-free protocol, only 7 percent of treatments required anticoagulation [<a href="#rid12">12</a>]. Given the low reported incidence of clotting, some clinicians do not routinely use heparin unless clotting occurs.</p><p class="headingAnchor" id="H4"><span class="h2">Vascular access</span><span class="headingEndMark"> — </span>TPE can be performed with any vascular access compatible with standard hemodialysis since the blood-flow requirements are modest. Standard TPE with centrifugal devices can often be performed with bilateral antecubital vein catheters. This approach is less likely to be successful with an MPS system, in which the blood-flow rate is frequently between 100 and 150 mL/min. However, removal of a larger catheter, such as a large bore, double-lumen catheter, is potentially hazardous after an intensive run of TPE due to a substantial "depletion" coagulopathy [<a href="#rid16">16,22</a>]. (See  <a class="medical medical_review" href="/d/html/7942.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Complications"</a>.)</p><p class="headingAnchor" id="H764476899"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasmapheresis without centrifugation devices</strong> – Therapeutic plasma exchange (TPE; plasmapheresis) may be performed by membrane plasma separation (MPS), which uses a standard dialysis machine in dialysis-bypass mode. TPE is also possible using dual-purpose NxStage and Prismaflex (continuous kidney replacement therapy [CKRT]) machines. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technical considerations</strong> – The membrane most commonly used for this purpose in the United States is the Plasmaflo filter. The Plasmaflo filter should be operated with a very modest transmembrane pressure (TMP &lt;75 mmHg) and blood flow (50 to 150 mL/min) in order to minimize the tendency to hemolysis and filter clotting. Limiting TMP can be achieved by limiting blood flow. (See <a class="local">'Technical considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulation</strong> – Most TPE treatments performed with standard centrifugal devices use citrate anticoagulation. Although this technique can be modified for use with an MPS system, most MPS treatments are performed with heparin. A bolus of low-dose heparin (eg, 2000 units) can be given at the start of the treatment, unless anticoagulation is contraindicated. However, given the low reported incidence of clotting, some clinicians do not routinely use heparin unless clotting occurs. (See <a class="local">'Anticoagulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular access</strong> – TPE can be performed with any vascular access compatible with standard hemodialysis. Removal of a larger catheter, such as a large bore, double-lumen catheter, is potentially hazardous after an intensive run of TPE due to a substantial "depletion" coagulopathy. (See <a class="local">'Vascular access'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Sowada K, Malchesky PS, Nose Y. Available removal systems: State of the art. In: Therapeutic Hemapheresis in the 1990s, Nydegger UE (Ed), Karger, Basel 1990. Vol 57, p.51.</li><li><a class="nounderline abstract_t">Williams ME, Balogun RA. Principles of separation: indications and therapeutic targets for plasma exchange. Clin J Am Soc Nephrol 2014; 9:181.</a></li><li><a class="nounderline abstract_t">Gurland HJ, Lysaght MJ, Samtleben W, Schmidt B. A comparison of centrifugal and membrane-based apheresis formats. Int J Artif Organs 1984; 7:35.</a></li><li><a class="nounderline abstract_t">Gurland HJ, Lysaght MJ, Samtleben W, Schmidt B. Comparative evaluation of filters used in membrane plasmapheresis. Nephron 1984; 36:173.</a></li><li><a class="nounderline abstract_t">Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008; 52:1180.</a></li><li><a class="nounderline abstract_t">Kaplan AA. Why nephrologists should do therapeutic plasma exchange. Dial Transplant 2009; 38:65.</a></li><li><a class="nounderline abstract_t">Ahmed S, Kaplan A. Therapeutic Plasma Exchange Using Membrane Plasma Separation. Clin J Am Soc Nephrol 2020; 15:1364.</a></li><li><a class="nounderline abstract_t">Nagano T, Nakazono K, Iwamoto H, et al. Comparative study of polyethylene plasma separator sterilized by ethylene oxide and gamma rays. Jpn J Apheresis 1997; 16:297.</a></li><li><a class="nounderline abstract_t">Gerhardt RE, Ntoso KA, Koethe JD, et al. Acute plasma separation with hemodialysis equipment. J Am Soc Nephrol 1992; 2:1455.</a></li><li><a class="nounderline abstract_t">Howard RL, Tatum K, Chan L, Shapiro JI. Performance of plasmapheresis by nephrologists: A survey. Dial Transplant 1990; 19:484.</a></li><li><a class="nounderline abstract_t">Grandham S, Yousaf F, Win Y, et al. Therapeutic plasmapheresis in primary presentation of diabetes mellitus with diabetic ketoacidosis, hypertriglyceridemia and acute pancreatitis. World J Nephrol Urol 2014; 3:162.</a></li><li><a class="nounderline abstract_t">Gashti CN, Andreoli DC, Patel D. Membrane-based therapeutic plasma exchange (mTPE): Technical and clinical experience. J Clin Apher 2018; 33:38.</a></li><li><a class="nounderline abstract_t">Malchesky PS, Koo AP, Roberson GA, et al. Apheresis technologies and clinical applications: the 2005 International Apheresis Registry. Ther Apher Dial 2007; 11:341.</a></li><li><a class="nounderline abstract_t">Price CA. Therapeutic plasma exchange in a dialysis unit. ANNA J 1987; 14:103.</a></li><li><a class="nounderline abstract_t">Lim E, Kim Y, Jeong JC, et al. Clinical analysis of single filtration plasmapheresis using continuous renal replacement therapy machines in kidney transplantation. Kidney Res Clin Pract 2017; 36:192.</a></li><li><a class="nounderline abstract_t">Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994; 23:817.</a></li><li><a class="nounderline abstract_t">Price CA, McCarley PB. Technical considerations of therapeutic plasma exchange as a nephrology nursing procedure. ANNA J 1993; 20:41.</a></li><li><a class="nounderline abstract_t">Price CA, McCarley PB. Physical assessment for patients receiving therapeutic plasma exchange. ANNA J 1994; 21:149.</a></li><li><a class="nounderline abstract_t">Ilamathi E, Kirsch M, Moore B, Finger M. Citrate anticoagulation during plasmapheresis using standard hemodialysis equipment. Semin Dial 1993; 6:268.</a></li><li><a class="nounderline abstract_t">Frascà GM, Buscaroli A, Borgnino LC, Vangelista A. Optimization of heparin anticoagulation during membrane plasma separation. Int J Artif Organs 1988; 11:313.</a></li><li><a class="nounderline abstract_t">Córdoba JP, Larrarte C, Medina MC. Experience in therapeutic plasma exchange by membrane filtration at an academic center in Colombia: Registry of the first 500 sessions. J Clin Apher 2015; 30:347.</a></li><li><a class="nounderline abstract_t">Kaplan AA, Halley SE. Plasma exchange with a rotating filter. Kidney Int 1990; 38:160.</a></li></ol></div><div id="topicVersionRevision">Topic 1864 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sowada K, Malchesky PS, Nose Y. Available removal systems: State of the art. In: Therapeutic Hemapheresis in the 1990s, Nydegger UE (Ed), Karger, Basel 1990. Vol 57, p.51.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24178973" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Principles of separation: indications and therapeutic targets for plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6698631" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A comparison of centrifugal and membrane-based apheresis formats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6700809" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparative evaluation of filters used in membrane plasmapheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18562061" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Therapeutic plasma exchange: core curriculum 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Why nephrologists should do therapeutic plasma exchange</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32312791" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Therapeutic Plasma Exchange Using Membrane Plasma Separation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparative study of polyethylene plasma separator sterilized by ethylene oxide and gamma rays</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1627768" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute plasma separation with hemodialysis equipment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Performance of plasmapheresis by nephrologists: A survey</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Therapeutic plasmapheresis in primary presentation of diabetes mellitus with diabetic ketoacidosis, hypertriglyceridemia and acute pancreatitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28608569" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Membrane-based therapeutic plasma exchange (mTPE): Technical and clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17845394" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Apheresis technologies and clinical applications: the 2005 International Apheresis Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3647758" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Therapeutic plasma exchange in a dialysis unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28680827" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical analysis of single filtration plasmapheresis using continuous renal replacement therapy machines in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8203364" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Therapeutic plasma exchange: complications and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8431026" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Technical considerations of therapeutic plasma exchange as a nephrology nursing procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8080323" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Physical assessment for patients receiving therapeutic plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Citrate anticoagulation during plasmapheresis using standard hemodialysis equipment</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3410572" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Optimization of heparin anticoagulation during membrane plasma separation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25708454" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Experience in therapeutic plasma exchange by membrane filtration at an academic center in Colombia: Registry of the first 500 sessions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2385083" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Plasma exchange with a rotating filter.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
